{"url_path":"/sec/spro/8-k/2026-07-14/item-8-01","section_key":"item-8-01","section_title":"Item 8.01 Other Events.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-07-14","source_url":"https://www.sec.gov/Archives/edgar/data/1701108/0001193125-26-302473-index.html","accession_number":"0001193125-26-302473","cik":"0001701108","ticker":"SPRO","issuer_name":"Spero Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1701108/0001193125-26-302473-index.html","primary_entity_key":"0001701108","primary_entity_name":"Spero Therapeutics, Inc."},"word_count":469,"has_tables":true,"body_markdown":"Item 8.01\n\nOther Events.\n\nCash Runway\n\nBased upon the Company’s current plans and forecasted expenses, the Company estimates that the net proceeds from the royalty financing transaction, together with the Company’s existing cash and cash equivalents, will enable the Company to fund its operating expenses and capital expenditure requirements into the second half of 2029. The Company has based this estimate on assumptions that may prove to be wrong, and the Company could use its available capital resources sooner than it currently expects.\n\nCautionary Note Regarding Forward Looking Statements\n\nThis Current Report on Form 8-K contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, including, without limitation, statements regarding the Company’s potential payment of certain milestone payments as well as royalty payments on net sales in connection with the Innovent Agreement; statements regarding the Company’s future plans or expectations for SP001, including plans and timing with respect to future clinical trials as well as trial design; statements regarding the Company’s receipt of payments pursuant to the NPA and RPA; and statements regarding the Company’s cash runway. In some cases, forward-looking statements may be identified by terms such as “may,” “will,” “should,” “expect,” “plan,” “aim,” “anticipate,” “could,” “intent,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “potential” or “continue,” the negative of these terms or other similar expressions; however, the absence of these words does not mean that statement is not forward looking. Any forward-looking statements in this Current Report are based on management’s current expectations and beliefs and are subject to a number of important risks, uncertainties and other factors that may cause actual results to differ materially from those indicated by such forward looking statements, including the anticipated benefits from the Innovent Agreement and the NPA and RPA; the risks associated with the Company’s ability to maintain the Innovent Agreement and the NPA and RPA; the Company’s expectations regarding the potential therapeutic benefits of SP001; the Company’s expectations for clinical and preclinical development, including additional IND filings, expansion into additional indications and geographies, enrollment in clinical trials, and availability of clinical trial data; the implementation of the Company’s business model and strategic plans for our business and current and future product candidates; the Company’s need for\n\nadditional funding; the Company’s ability to retain key personnel; whether the Company’s cash resources will be sufficient to fund its continuing operations for the periods anticipated; and other factors discussed in the “Risk Factors” set forth in filings that the Company periodically makes with the Securities Exchange Commission. The forward-looking statements included in this Current Report represent the Company’s views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date. Except as required by law, the Company explicitly disclaims any obligation to update any forward-looking statements."}